Teva Pharmaceuticals International and mAbxience, a Fresenius Kabi majority-owned group, have announced a new global licensing agreement for an additional oncology biosimilar candidate.
Financial details of the agreement were not disclosed.
The agreement focuses on developing an anti-PD-1 biosimilar. It is the second agreement between the two companies, building on their collaboration that began in April 2024.
The latest deal further strengthens the partnership between mAbxience and Teva Pharmaceuticals International, a subsidiary of Israel-based Teva Pharmaceutical Industries.
Both partners aim to deliver cost-effective, biosimilars to meet critical needs in oncology care.
In addition, the collaboration promotes innovation and enhances healthcare accessibility, benefiting patients worldwide.
The licensing agreement grants exclusive rights for multiple markets, including Europe and the US. This also aligns with mAbxience’s strategy for global expansion.
It also supports Teva Pharmaceuticals’ growth strategy by adding a new biosimilar to its portfolio.
mAbxience CEO Jurgen Van Broeck said: “Building on our first agreement with Teva signed earlier this year, this second collaboration is a testament to the strength of our partnership and the shared vision of both companies.
“This agreement reinforces our commitment to making high-quality biosimilars accessible and improving healthcare outcomes on a global scale.”
Under the terms of this agreement, mAbxience will lead the development and production of the biosimilar. The firm will utilise its cGMP-compliant facilities in Spain and Argentina.
On the other hand, Teva Pharmaceuticals will handle regulatory approvals and oversee commercialisation in designated markets.
The collaboration aims to ensure global access to this oncology treatment for patients.
Teva Pharmaceuticals business development executive vice president Angus Grant said: “This collaboration with mAbxience reflects Teva’s ideal strategic partnership model to optimise development costs, apply our regulatory expertise and leverage our extensive commercial capabilities to bring new treatment options to people living with serious medical conditions.”
mAbxience is a Spanish company focused on the development, production, and commercialisation of biopharmaceuticals.
In August 2022, Fresenius Kabi acquired a majority stake in mAbxience for €495m plus contingent payments.
The Spanish firm has two market-approved products a strong pipeline in development and three multi-product facilities in Europe and South America.
In September 2023, mAbxience collaborated with Abbott to commercialise several biosimilars aiming for oncology, women’s health, and respiratory diseases in emerging markets.
